<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658095</url>
  </required_header>
  <id_info>
    <org_study_id>07062</org_study_id>
    <nct_id>NCT04658095</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Multicenter Study To Compare The Safety And Effectiveness Of The OMNI® Surgical System And The iStent Inject In Pseudophakic Eyes With Open Angle Glaucoma. The TRIDENT European Trial</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Study To Compare The Safety And Effectiveness Of The OMNI® Surgical System And The iStent Inject In Pseudophakic Eyes With Open Angle Glaucoma. The TRIDENT European Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sight Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using&#xD;
      the OMNI Surgical System to implantation of the iStent inject in lowering intraocular&#xD;
      pressure (IOP) in pseudophakic eyes with open angle glaucoma (OAG), and second, to compare&#xD;
      safety and effectiveness outcomes for canaloplasty alone (using the OMNI Surgical System)to&#xD;
      implantation of the iStent Inject in lowering IOP in pseudophakic eyes with OAG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in unmedicated DIOP from baseline at the 12-month postoperative examination</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">459</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ab-interno implantation of iStent inject (2 microstents)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMNI® Surgical System</intervention_name>
    <description>Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System</description>
    <arm_group_label>Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent inject</intervention_name>
    <description>Ab-interno implantation of iStent inject (2 microstents)</description>
    <arm_group_label>Ab-interno implantation of iStent inject (2 microstents)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMNI® Surgical System</intervention_name>
    <description>Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System</description>
    <arm_group_label>Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, 18 years or older&#xD;
&#xD;
          2. Pseudophakic&#xD;
&#xD;
          3. Diagnosis of open angle glaucoma (OAG)&#xD;
&#xD;
          4. On 1-5 ocular hypotensive medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following prior treatments for glaucoma:&#xD;
&#xD;
               -  Suprachoroidal stent (e.g. Cypass, iStent Supra)&#xD;
&#xD;
               -  Laser trabeculoplasty ≤ 8 weeks prior to Baseline visit with a MIGS or other&#xD;
                  glaucoma device including but not limited to iStent, iStent inject, Hydrus,&#xD;
                  CyPass&#xD;
&#xD;
               -  Trabeculectomy or other bleb forming procedure including Xen, PreserFlo, Express,&#xD;
                  glaucoma draining device/valve&#xD;
&#xD;
               -  Prior canaloplasty, goniotomy, or trabeculotomy including procedures with GATT,&#xD;
                  Kahook Dual Blade, iTrack, Trabectome&#xD;
&#xD;
               -  Ciliary ablation procedures including Endocyclophotocoagulation (ECP),&#xD;
                  Cyclophotocoagulation (G probe), Micropulse laser, or high intensity focused&#xD;
                  ultrasound (HIFU)&#xD;
&#xD;
          2. Any other form of glaucoma other than OAG&#xD;
&#xD;
          3. Concurrent ocular pathology or systemic medical condition which, in the Investigator's&#xD;
             judgment, would either place the subject at increased risk of complications,&#xD;
             contraindicate surgery, place the subject at risk of significant vision loss during&#xD;
             the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular&#xD;
             infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere&#xD;
             with compliance to elements of the study protocol (e.g., returning to investigator's&#xD;
             office for follow-up visits).&#xD;
&#xD;
          4. Women of childbearing potential if they are currently pregnant or intend to become&#xD;
             pregnant during the study period; are breast-feeding; or are not in agreement to use&#xD;
             adequate birth control methods to prevent pregnancy throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kavita Dhamdhere, MD</last_name>
    <phone>877-266-1144</phone>
    <email>kdhamdhere@sightsciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BurgerHospital</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

